[Cell therapy in dilated cardiomyopathy]

Area of Science:

• Cardiology
• Regenerative Medicine
• Stem Cell Therapy

Background:

• Dilated cardiomyopathy (DCM) is a severe heart condition characterized by left ventricular enlargement and systolic dysfunction.
• Current treatments for advanced DCM often focus on managing symptoms and preventing further deterioration.
• Autologous bone marrow cell transplantation is being explored as a potential regenerative therapy for heart failure.

Observation:

• A 41-year-old male with NYHA FC-III, clinical stage C DCM underwent autologous bone marrow mononuclear cell transplantation via cardiac catheterization.
• The procedure was performed using the coronary artery system for cell delivery.
• The patient had no history of adverse events or hemodynamic instability prior to the procedure.

Findings:

• Two months post-transplant, significant improvements were observed, including reduced plasma BNP levels and decreased cardiac area on chest X-ray and MRI.
• Echocardiography revealed diminished secondary regurgitation and mitral ring dilatation.
• Ergospirometry showed improved exercise capacity with increased maximal oxygen consumption, allowing for reduced medication.

Implications:

• This case demonstrates the safety and feasibility of autologous bone marrow cell transplantation in treating dilated cardiomyopathy.
• The observed improvements suggest potential for cardiac regeneration and functional recovery in heart failure patients.
• This pioneering approach may offer a new therapeutic avenue for patients with advanced systolic heart failure.